The “vulnerable plaque” responsible for acute coronary syndromes and, ultimately, coronary artery thrombosis, has a thin cap and a necrotic core (see Atherosclerosis Topic Review). A key ...

For decades, the clinical approach to coronary artery disease has been centred on the acute effects of coronary occlusion and ...

The “vulnerable” plaque responsible for acute coronary syndromes and, ultimately, coronary artery thrombosis, has a thin cap and a necrotic core; see Atherosclerosis Topic Review. There are ...

Plaque disruption and subsequent thrombosis are recognized as critical processes contributing to the onset of acute coronary ischemic syndromes. Intravascular thrombus adhering to an underlying ...

Current guidelines recommend dual antiplatelet therapy, a combination of aspirin and a P2Y 12 inhibitor, for 6–12 months after percutaneous coronary intervention with drug-eluting stent ...